6.72  -0.04 (-0.59%)		04-18 16:00
Open: 6.83 High: 7.05 Volume: 77,120		Pre. Close: 6.76 Low: 6.56 Market Cap: 119(M)

Short term
Mid term
Targets	6-month :	11.56	1-year :	14.13
Resists	First :	9.89	Second :	12.1
Pivot price	7.46
Supports	First :	6.33	Second :	5.27
MAs	MA(5) :	6.77	MA(20) :	7.77
	MA(100) :	8.3	MA(250) :	11.62
MACD	MACD :	-0.6	Signal :	-0.5
%K %D	K(14,3) :	19.9	D(3) :	15.7
RSI	RSI(14): 35.7
52-week	High :	18.64	Low :	6.19

Price has closed below its short-term moving average. Short-term moving average is currently below mid-term; and below long-term moving average. From the relationship between price and moving averages: This stock is BEARISH in short-term; and NEUTRAL in mid-long term.
[ NVCT ] has closed above bottom band by 16.1%. Bollinger Bands are 2.9% narrower than normal. The current width of the bands does not suggest anything about the future direction or movement of prices.

If tomorrow:	Open lower	Open higher
High:	7.06 - 7.1	7.1 - 7.15
Low:	6.45 - 6.5	6.5 - 6.54
Close:	6.64 - 6.71	6.71 - 6.8

Nuvectis Pharma, Inc., a biopharmaceutical company, focuses on the development of precision medicines for the treatment of serious unmet medical needs in oncology. It develops NXP800, a novel heat shock factor 1 pathway inhibitor for the treatment of various cancers; and NXP900, a small molecule drug candidate to inhibit the Proto-oncogene c-Src and YES1 kinases. The company was incorporated in 2020 and is based in Fort Lee, New Jersey.

Wed, 17 Apr 2024
Is Nuvectis Pharma (NASDAQ:NVCT) In A Good Position To Deliver On Growth Plans? - Yahoo Finance

Thu, 11 Apr 2024
Nuvectis Pharma, Inc. Expected to Earn Q1 2024 Earnings of ($0.39) Per Share (NASDAQ:NVCT) - MarketBeat

Wed, 10 Apr 2024
Nuvectis Pharma (NASDAQ:NVCT) Shares Down 1.5% - MarketBeat

Mon, 08 Apr 2024
Nuvectis Pharma's NXP900 Demonstrates Robust Activity in Non-Small Cell Lung Cancer Cell Lines - GlobeNewswire

Tue, 26 Mar 2024
NVCT Stock Quote Price and Forecast - CNN

Thu, 21 Mar 2024
Insider Buying: Nuvectis Pharma Co-Founder Bought US$51k Of Shares - Simply Wall St

Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly.	Outperform
Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS).	Underperform
Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows.	Neutral
Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit.	Underperform
Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency.	Underperform
Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn.	Neutral

Exchange: NASDAQ
Sector: Healthcare
Industry: Biotechnology
Shares Out	18 (M)
Shares Float	5 (M)
Held by Insiders	57.2 (%)
Held by Institutions	17 (%)
Shares Short	808 (K)
Shares Short P.Month	724 (K)

EPS	-1.43
EPS Est Next Qtrly	0
EPS Est This Year	0
EPS Est Next Year	0
Book Value (p.s.)	0.69
Profit Margin	0 %
Operating Margin	0 %
Return on Assets (ttm)	-69.2 %
Return on Equity (ttm)	-168.6 %
Qtrly Rev. Growth	0 %
Gross Profit (p.s.)	0
Sales Per Share	0
EBITDA (p.s.)	0
Qtrly Earnings Growth	0 %
Operating Cash Flow	-16 (M)
Levered Free Cash Flow	-8 (M)

PE Ratio	-4.7
PEG Ratio	0
Price to Book value	9.59
Price to Sales	0
Price to Cash Flow	-7.49

Dividend	0
Forward Dividend	0
Dividend Yield	0%
Dividend Pay Date	Invalid DateTime.
Ex-Dividend Date	Invalid DateTime.